Opinion

Video

Myelofibrosis: Characteristics and Subtypes

Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.

This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.

Myelofibrosis, a myeloproliferative neoplasm, manifests in variable blood counts and constitutional symptoms. Gerds explains its impact, causing cytokine-driven symptoms like night sweats and spleen enlargement. The disease's clonal nature poses a risk of progression to the blast phase, a highly aggressive stage. Understanding these clinical aspects is crucial for effective management.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
4 KOLs are featured in this series
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
Doctors planning DMD treatment | Image Credit: OlegKachura - stock.adobe.com
January 24th 2024

DMD Guidance Could Benefit From Update, Experts Say

Maggie L. Shaw
MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Neoplasms, cancerous disease, malignant tumour | Ирина Батюк - stock.adobe.com
January 23rd 2024

NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis

Pearl Steinzor
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023

NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera

Rose McNulty
Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
b-cell lymphoma
June 23rd 2023

NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for DLBCL

Caroline Seymour
Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.
Businessman hand checking the interview evaluation paper for job interview at office background, job search, business concept: © mangpor2004 - stock.adobe.com
June 16th 2023

Review Finds EORTC QLQ-MY20 Useful, Robust 25 Years After Development

Gianna Melillo
The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023

ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC

Rose McNulty
The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo